Hong Kong Pharma Digital Technology (NASDAQ:HKPD) Posts Earnings Results

Hong Kong Pharma Digital Technology (NASDAQ:HKPD) released its earnings results on Friday. The company reported ($0.04) earnings per share for the quarter, FiscalAI reports. The firm had revenue of $3.15 million for the quarter.

Hong Kong Pharma Digital Technology Price Performance

HKPD traded up $0.01 during trading on Friday, reaching $0.42. 17,812 shares of the stock traded hands, compared to its average volume of 1,493,557. The stock’s 50-day simple moving average is $0.42 and its two-hundred day simple moving average is $0.58. Hong Kong Pharma Digital Technology has a fifty-two week low of $0.31 and a fifty-two week high of $2.58.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Hong Kong Pharma Digital Technology stock. StoneX Group Inc. purchased a new stake in Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ:HKPD) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 43,284 shares of the company’s stock, valued at approximately $36,000. StoneX Group Inc. owned about 0.39% of Hong Kong Pharma Digital Technology as of its most recent filing with the Securities & Exchange Commission.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (d)” rating on shares of Hong Kong Pharma Digital Technology in a research note on Wednesday, July 29th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has an average rating of “Sell”.

Hong Kong Pharma Digital Technology Company Profile

Hong Kong Pharma is an exempted limited liability company formed under the laws of the Cayman Islands on August 17, 2023. As a holding company with no material operations of its own, Hong Kong Pharma conducts its operations through its wholly owned subsidiaries, Joint Cross Border Logistics Company Limited and V-Alliance Technology Supplies Limited, each a limited liability corporation incorporated in Hong Kong and collectively referred to as HK Subsidiaries. Our business offering consists of two main categories: (i) OTC pharmaceutical cross-border e-commerce supply chain services, primarily conducted through our Hong Kong subsidiary, Joint Cross Border, which we refer to as the “Supply Chain Services” division and (ii) OTC pharmaceutical cross-border procurement and distribution, primarily conducted through our Hong Kong subsidiary, V-Alliance, which we refer to as the “Procurement and Distribution” division.